Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) Director Joseph C. Scodari acquired 24,631 shares of the stock in a transaction dated Monday, January 6th. The shares were purchased at an average price of $1.01 per share, for a total transaction of $24,877.31. Following the completion of the purchase, the director now directly owns 27,708 shares in the company, valued at $27,985.08. The trade was a 800.49 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Acurx Pharmaceuticals Price Performance
NASDAQ:ACXP opened at $0.75 on Thursday. The company has a market cap of $12.69 million, a P/E ratio of -0.69 and a beta of -1.71. The firm’s fifty day moving average price is $1.19 and its two-hundred day moving average price is $1.78. Acurx Pharmaceuticals, Inc. has a one year low of $0.68 and a one year high of $5.28.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter last year, the business posted ($0.24) earnings per share. As a group, equities research analysts expect that Acurx Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Report on ACXP
Hedge Funds Weigh In On Acurx Pharmaceuticals
A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC lifted its position in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) by 6.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 295,075 shares of the company’s stock after buying an additional 16,975 shares during the quarter. Prospect Financial Services LLC owned about 1.86% of Acurx Pharmaceuticals worth $561,000 as of its most recent SEC filing. 11.53% of the stock is currently owned by institutional investors.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Further Reading
- Five stocks we like better than Acurx Pharmaceuticals
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why AMD Stock Might Already Be This Year’s Best Buy
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Promising Penny Stocks to Watch for Long-Term Gains in 2025
- Stock Market Upgrades: What Are They?
- The 3 Kings of Buybacks in 2024: Can They Do It Again?
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.